Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM2020 in advanced solid tumors
NCT07098052Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- Aug 2025
- Primary completion
- Sep 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HDM2020 in solid tumor, sponsored by Huadong Medicine. Primary endpoints: Maximal Tolerance Dose at 21 days and Incidence of Treatment-Emergent Adverse Events at 1 year. Started Aug 2025; status: recruiting.
02
Drugs
HDM2020
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07098052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07098052.